Incyte has announced a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal valued at $1.25 billion upfront, with the potential for an additional $750 million tied to future sales milestones. The transaction could reach a total value of $2 billion and is expected to strengthen Incyte’s position in the hematology market through the addition of Vega’s lead investigational therapy, VGA039.
The acquisition brings to Incyte a late-stage asset that is currently in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding disorder. VGA039 is a novel monoclonal antibody designed to modulate Protein S, a key regulator of blood clotting, with the goal of improving the body’s ability to control bleeding episodes.
The therapy has generated significant interest because of its potential to become the first subcutaneous prophylactic treatment for patients with VWD. Current preventive treatment options often require intravenous factor replacement therapies administered two to three times per week, creating a substantial burden for patients. A convenient injectable therapy could represent a major advancement in disease management and improve quality of life for individuals living with the condition.
According to Incyte Chief Executive Officer Bill Meury, VGA039 aligns closely with the company’s strategy of building a long-term growth portfolio focused on innovative treatments in core therapeutic areas. He described the candidate as a first-in-class Phase 3 asset with promising early clinical data, a clear development pathway, and significant commercial potential.
Von Willebrand disease affects an estimated 135,000 diagnosed individuals in the United States. The condition is characterized by excessive and sometimes unpredictable bleeding that can vary in severity, often impacting daily activities and overall well-being.
VGA039 has already received several important regulatory designations from the U.S. Food and Drug Administration, including Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease status. These designations are intended to support and accelerate the development of therapies targeting serious diseases with unmet medical needs.
The drug candidate is currently being evaluated in the Phase 3 VIVID-6 clinical trial, a global single-arm crossover study designed to assess the safety and efficacy of subcutaneous VGA039 as a preventive treatment for bleeding in patients across all types of von Willebrand disease, including those with significant disease burden.
Adam Rosenthal, founder and chief executive officer of Star Therapeutics, said the agreement reflects the company’s commitment to developing innovative therapies for serious conditions. He expressed confidence that Incyte’s expertise in hematology and proven commercial capabilities would help advance VGA039 toward potential regulatory approval and broader patient access.
The boards of directors of both companies have approved the transaction. Under the terms of the agreement, Incyte will acquire all outstanding shares of Vega Therapeutics. The deal remains subject to customary closing conditions, including regulatory review under the Hart-Scott-Rodino Antitrust Improvements Act.
The acquisition is expected to close during the third quarter of 2026. Incyte anticipates recording an approximately $1.25 billion research and development charge related to the transaction in its third-quarter and full-year 2026 financial results. Financial advisors on the deal include Lazard for Incyte, while Evercore and Morgan Stanley are advising Star Therapeutics.